Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
NewsThe FDA has approved Ryzumvi (phentolamine ophthalmic solution 0.75%), a preservative-free eye drop, for the treatment of presbyopia — the age-related blurring of near vision that affects roughly 90% of Americans over 45. Backed by phase 3 trial data, the drop works by shrinking pupil size without engaging the ciliary muscle, improving near vision while keeping distance vision intact.
The FDA has approved a supplemental new drug application for Ryzumvi (phentolamine ophthalmic solution 0.75%), a preservative-free eye drop for the treatment of presbyopia — the common age-related condition that makes reading, scrolling, and screen time a challenge. The approval marks a new pharmacological option for the millions of adults who currently rely on reading glasses or corrective lenses.
Ryzumvi works through a sympatholytic mechanism, reducing pupil diameter without engaging the ciliary muscle. This approach improves near vision while preserving distance vision. The drug was already FDA-approved in 2023 for pharmacologically induced mydriasis, and this latest approval expands its indication. Viatris holds exclusive U.S. commercialization rights under a global licensing agreement with Opus Genetics.
By the Numbers:
Why it matters: Presbyopia is one of the most widespread vision conditions in the world, yet treatment options beyond corrective lenses have been limited. Ryzumvi offers a convenient, noninvasive daily drop that could meaningfully improve quality of life for tens of millions of adults.
